Context Capital Management’s Peak Bio, Inc. Common Stock PKBO Stock Holding History

Context Capital Management’s Portfolio PKBO Stock Details PKBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-50,000	Closed	-$499K	–	537
2022 Q3	$499K	Hold	50,000	–	–	0.03%	322
2022 Q2	$493K	Hold	50,000	–	–	0.04%	344
2022 Q1	$492K	Buy	+50,000	New	+$491K	0.03%	384

Other funds holding PKBO

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Context Capital Management's PKBO Position: Q4 2022 in Review

Context Capital Management sold out of Peak Bio, Inc. Common Stock (PKBO) in Q4 2022, closing a stake of 50,000 shares — an estimated $499K sold.

Context Capital Management first reported a position in PKBO in Q1 2022 and held it in 3 quarters. The position peaked at $499K in Q3 2022. 9 funds tracked by Wall St. Rank hold PKBO as of Q4 2022.

Context Capital Management reported no remaining Peak Bio, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Context Capital Management sold 50,000 Peak Bio, Inc. Common Stock shares in Q4 2022, an estimated $499K.
Context Capital Management first reported a position in Peak Bio, Inc. Common Stock in Q1 2022 and held it in 3 quarters.
Context Capital Management's Peak Bio, Inc. Common Stock position peaked at $499K in Q3 2022.
9 funds tracked by Wall St. Rank held Peak Bio, Inc. Common Stock as of Q4 2022.

Based on Context Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.